Optivise Advisory Services’s FibroBiologics FBLG Stock Holding History

Optivise Advisory Services’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,505	Closed	-$24.8K	–	218
2025 Q4	$24.8K	Hold	5,505	–	–	0.01%	199
2025 Q3	$60.1K	Hold	5,505	–	–	0.04%	195
2025 Q2	$68.5K	Hold	5,505	–	–	0.04%	204
2025 Q1	$99.1K	Hold	5,505	–	–	0.06%	193
2024 Q4	$220K	Hold	5,505	–	–	0.12%	158
2024 Q3	$340K	Hold	5,505	–	–	0.18%	108
2024 Q2	$549K	Buy	+5,505	New	+$1.05M	0.3%	77

Other funds holding FBLG

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FEG

Fund Evaluation Group Cincinnati, Ohio $3.25B AUM 14.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CFP

Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

VGA

Vanguard Global Advisers Malvern, Pennsylvania $187B AUM

Optivise Advisory Services's FBLG Position: Q1 2026 in Review

Optivise Advisory Services sold out of FibroBiologics (FBLG) in Q1 2026, closing a stake of 5,505 shares — an estimated $24.8K sold.

Optivise Advisory Services first reported a position in FBLG in Q2 2024 and held it in 7 quarters. The position peaked at $549K in Q2 2024. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

Optivise Advisory Services reported no remaining FibroBiologics position as of Q1 2026 after selling out during the quarter.
Optivise Advisory Services sold 5,505 FibroBiologics shares in Q1 2026, an estimated $24.8K.
Optivise Advisory Services first reported a position in FibroBiologics in Q2 2024 and held it in 7 quarters.
Optivise Advisory Services's FibroBiologics position peaked at $549K in Q2 2024.
17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on Optivise Advisory Services's 13F filing for Q1 2026, filed 15 Apr 2026.